about
To Wnt or Lose: The Missing Non-Coding Linc in Colorectal Cancer.Peptidylprolyl Isomerases as In Vivo Carriers for Drugs That Target Various Intracellular Entities.ATAD2 in cancer: a pharmacologically challenging but tractable target.Trial watch: Immune checkpoint blockers for cancer therapy.Structure-based drug design: aiming for a perfect fit.Current Advances in Aptamers for Cancer Diagnosis and Therapy.Cancer systems biology: Harnessing off-target effects.Alpha-Difluoromethylornithine, an Irreversible Inhibitor of Polyamine Biosynthesis, as a Therapeutic Strategy against Hyperproliferative and Infectious Diseases.Aptamers and apple pies: a mini-review of PSMA aptamers and lessons from Donald S. Coffey.Characterization of clinically used oral antiseptics as quadruplex-binding ligands.A modified gene trap approach for improved high-throughput cancer drug discovery.The MYC oncogene is a global regulator of the immune response.BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC.Dysregulation of mitochondrial dynamics proteins are a targetable feature of human tumors.Interaction between Wnt/β-catenin and RAS-ERK pathways and an anti-cancer strategy via degradations of β-catenin and RAS by targeting the Wnt/β-catenin pathway.Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Neuroinflammatory Disorders: Targeting Chemokines/Cytokines.Targeting the spliceosome for cutaneous squamous cell carcinoma therapy: a role for c-MYC and wild-type p53 in determining the degree of tumour selectivity.Activation of Rho Family GTPases by Small Molecules.Chemical and structural studies provide a mechanistic basis for recognition of the MYC G-quadruplexTargeted Intracellular Delivery of Antibodies: The State of the Art
P2860
Q41660291-AA2B6446-4746-4711-AEB3-1A74CDF5A0CEQ47134039-B68B66FC-9E91-4F96-AA48-08436DCDB78AQ47392240-EF4D3887-6904-4944-B2AF-9ACF808589BAQ47393365-A1FF627F-0523-4E0F-A31F-7B58ED51F004Q47423892-BEB252C0-6EFC-457B-9E09-3782EC684BF7Q47561686-C7DEC620-0BED-4960-957C-A1F276C50467Q48261677-A12CC2A2-EFCE-4BD2-904A-57395B742FC3Q48506495-08A20039-10E4-4601-B177-E10835A8F658Q52581725-E53DB978-F8F0-431A-8B70-B74022618678Q52685061-ACFC171C-6A77-4924-8485-38715A5F26EAQ52714926-C9A2596C-8CE8-49FB-8B2A-4597F0688DB9Q52728139-ED5017F6-2678-4379-A93E-E34C9D1AF5B3Q52803469-2E8D0F68-D3A6-4880-9179-A34E3BFAA582Q54952243-EE734CDE-3C63-4C80-B4C7-8411ECFFAD7FQ54976921-8D3962C7-754D-4174-A45A-9E13119E93ECQ55052878-774B88E0-7C32-4031-9CBA-0AD670962E3BQ55137359-E0CAC115-D89A-4356-B64D-9F83799236CBQ55384170-8F9146E6-AADB-4044-B0E7-48D0CBA53979Q57471938-6288CE82-83E6-4220-84A4-CD6E2F9AA251Q58566968-8A40EDB8-5021-4B21-9DEE-142DE7E75E0E
P2860
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Drugging the 'undruggable' cancer targets.
@en
type
label
Drugging the 'undruggable' cancer targets.
@en
prefLabel
Drugging the 'undruggable' cancer targets.
@en
P2093
P2860
P356
P1476
Drugging the 'undruggable' cancer targets.
@en
P2093
Chi V Dang
E Premkumar Reddy
Kevan M Shokat
P2860
P2888
P304
P356
10.1038/NRC.2017.36
P407
P50
P577
2017-06-23T00:00:00Z
P6179
1086126312